No abstract

Background Whilst warts and vitiligo are both common skin diseases, their co-morbidity is rare. Here we present a clinical case of warts with vitiligo to illustrate the utility of individualized homeopathic treatment. Method The homeopathic medicine Sepia officinalis was prescribed, based on individualization. During follow-up, changes were documented by photographs. The non-invasive methods ORIDL (Outcome Related to Impact on Daily Living), VASI (Vitiligo Area and Scoring Index), and VETF (Vitiligo European Task Force) were used to assess treatment progress. Possible causal attribution of outcome with treatment was evaluated using the Modified Naranjo Criteria for Homeopathy (MONARCH). Result There was a marked improvement of vitiligo, along with the disappearance of warts, as evidenced photographically. VASI and VETF scores were significantly reduced. Main complaints, as well as overall well-being, improved on the ORIDL scale (+3). The MONARCH score (+9) suggested that the clinical improvement was attributable to the homeopathic intervention. Conclusion The study suggests a significant role for individualized homeopathic treatment in the co-morbidity of warts and vitiligo.

Patients with psoriasis commonly opt for homeopathic treatment. However, no study has assessed the response to homeopathic treatment by using standardized disease-specific scales, and the findings are based on clinical assessments only. The objective of this study was to evaluate the response to the individualized homeopathic treatment of psoriasis with respect to changes in disease severity and quality of life based on Psoriasis Area and Severity Index (PASI) and Psoriasis Disability Index (PDI) scales, respectively. A multicentric study was conducted using a pragmatic model. The study participants were regularly followed up for 1 year. Subsequently, participants completing the 1-year follow-up were included in a long-term assessment for further 2 years. Three monthly assessments were made by using PASI, PDI, and Visual Analog scales for patient and physician general assessment. Data were analyzed to identify treatment effects and variables affecting treatment. In total, 384 patients were enrolled, out of whom 254 participants completed 1 year of treatment. Of these, 84 participants continued treatment for an additional 12 months. A significant reduction was observed in the scores of PASI (10.96 ± 10.67 at baseline to 4.24 ± 5.10 at 12 months, p = 0.000), PDI (10.19 ± 9.11 to 3.91 ± 4.44, p = 0.000), and patient and physician global assessment scales. Regarding PASI response at 12 and 24 months, PASI 75–89 was reported in 66 and 14 participants, whereas PASI 90–100 was reported in 29 and 17 participants, respectively. Baseline severity of psoriasis considerably affected treatment response, whereas age, gender, and duration of psoriasis did not. Furthermore, the severity of psoriasis and quality of life improved considerably with regular homeopathic treatment.

No abstract